Roquefort Therapeutics (LON:ROQ) Shares Down 7.8% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 7.8% during mid-day trading on Monday . The stock traded as low as GBX 3.80 ($0.05) and last traded at GBX 3.80 ($0.05). Approximately 3,429,708 shares changed hands during mid-day trading, an increase of 525% from the average daily volume of 548,336 shares. The stock had previously closed at GBX 4.12 ($0.05).

Roquefort Therapeutics Stock Performance

The firm has a fifty day moving average price of GBX 4.07 and a two-hundred day moving average price of GBX 4.24. The stock has a market capitalization of £5.42 million, a PE ratio of -420.00 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.